December 29, 2015
Nectar Lifesciences appoints Additional Independet Director
Nectar Lifesciences appoints Additional Independet Director
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
December 29, 2015
Sanofi’s vaccines division gets Dengvaxia approval in Brazil
Sanofi Pasteur, the vaccines division of Sanofi, has gotten from Brayil regulatory approval to Dengvaxia. As the company said Monday ,…
December 28, 2015
Valeant CEO Pearson remains hospitalised for pneumonia – Bloomberg
Valeant Pharmaceuticals International Inc Chief Executive J. Michael Pearson has been moved to another hospital where he is being treated for a severe case of pneumonia
December 28, 2015
Jochen Gann BI’s first director of Hikma
Hikma Board has appointed Dr. Jochen Gann as BI’s first nominated director.
December 22, 2015
Glenmark’s Linezolid, version of Pfizer’s Zyvox, gets nod from FDA
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Linezolid Tablets, 600 mg, the therapeutic equivalent of Zyvox Tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer, Inc.
December 22, 2015
FDA approves India’s Aurobindo’s generic version of Alcon’s Patanol
Aurobindo Pharma Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% which makes the product is ready for launch.
December 22, 2015
Janssen and Bavarian Nordic to develop vaccine for Chronic Human Papillomavirus (HPV) infections
Janssen Pharmaceuticals, Inc. (Janssen) has entered into a definitive collaboration and license agreement with Bavarian Nordic to leverage their MVA-BN technology, jointly with Janssen’s own AdVac technology, in the development and commercialization of a heterologous prime-boost vaccine for the treatment of Human Papillomavirus (HPV) chronic infections which can lead to cancer.
December 21, 2015
Martin Shkreli attributes arrest to drug-price hikes – WSJ
Martin Shkreli, the pharmaceutical entrepreneur facing U.S. charges of securities fraud, has said he had been the target of legal authorities for his much-criticized drug-price hikes and his over-the-top public persona
December 18, 2015
Managerial changes for Parabolic Drugs Limited
Indian pharmaceutical company Parabolic Drugs Limited has made certain changes to its board of directors. Namely, the company announced on…
December 17, 2015
Bristol’s drug pricing under fire as UK agency rejects Opdivo
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.